AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE) to develop the potential first-in-class immunotherapy OSE-230, which is currently in the pre-clinical stage for the treatment of chronic and severe inflammation. Under the terms of the agreement, AbbVie will acquire exclusive global rights to develop, manufacture, and commercialize OSE-230 for an upfront payment of USD 48 million and potential milestone payments of up to USD 665 million, in addition to royalties on sales.
OSE-230 is a monoclonal antibody (mAb) designed to modulate the activity of macrophages and neutrophils by activating ChemR23, a G-Protein Coupled Receptor (GPCR) target. This innovative approach highlights the potential of OSE-230 in the immunotherapy space.
OSE Immunotherapeutics’ clinical pipeline is robust, featuring a range of immunotherapies including the cancer vaccine Tedopi, the anti-PD1 drug OSE-279, the IL-7 receptor antagonist lusvertikimab, the anti-CD28 biologic FR-104/VEL-101, and the anti-SIRPα monoclonal antibodies 765063 and BI 770371. The partnership with AbbVie is expected to bolster the development and potential commercial success of OSE-230, while also providing AbbVie with access to a promising new immunotherapy candidate.- Flcube.com
